

Kate Vandyke

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2890056/kate-vandyke-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

1,032
citations

21
h-index

32
g-index

43
ext. papers

1,240
ext. citations

5.5
avg, IF

4.17
L-index

#	Paper	IF	Citations
42	N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. <i>BMC Cancer</i> , 2018 , 18, 939	4.8	118
41	Dysregulation of bone remodeling by imatinib mesylate. <i>Blood</i> , 2010 , 115, 766-74	2.2	108
40	The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 1759-70	6.3	70
39	A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. <i>Blood</i> , 2019 , 134, 30-43	2.2	54
38	Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. <i>Leukemia</i> , 2009 , 23, 994-7	10.7	50
37	Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. <i>Journal of Molecular Endocrinology</i> , 2012 , 48, 229-40	4.5	46
36	Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells. <i>Stem Cells and Development</i> , 2016 , 25, 909-21	4.4	45
35	Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 3763-7	5.6	43
34	EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling. <i>FASEB Journal</i> , 2017 , 31, 1011-1027	0.9	42
33	Imatinib mesylate causes growth plate closure in vivo. <i>Leukemia</i> , 2009 , 23, 2155-9	10.7	39
32	EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 926-35	6.3	38
31	SAMSN1 is a tumor suppressor gene in multiple myeloma. <i>Neoplasia</i> , 2014 , 16, 572-85	6.4	33
30	HIF-2 α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. <i>Cancer Research</i> , 2017 , 77, 5452-5463	10.1	33
29	Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. <i>Neoplasia</i> , 2019 , 21, 777-787	6.4	30
28	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. <i>Oncotarget</i> , 2017 , 8, 43602-43616	3.3	29
27	Immunomodulatory Properties of Induced Pluripotent Stem Cell-Derived Mesenchymal Cells. <i>Journal of Cellular Biochemistry</i> , 2016 , 117, 2844-2853	4.7	26
26	The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. <i>European Journal of Haematology</i> , 2015 , 94, 343-54	3.8	24

25	PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 106	22.4	23
24	Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. <i>Experimental Cell Research</i> , 2015 , 332, 24-38	4.2	22
23	Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. <i>British Journal of Haematology</i> , 2015 , 171, 387-99	4.5	21
22	The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. <i>Blood Cancer Journal</i> , 2011 , 1, e2	7	21
21	Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 67-76	5.6	19
20	Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2013 , 161, 499-507	4.5	17
19	The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. <i>British Journal of Haematology</i> , 2017 , 177, 423-440	4.5	15
18	Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. <i>Biomacromolecules</i> , 2014 , 15, 1276-87	6.9	15
17	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. <i>Cancer Letters</i> , 2020 , 475, 99-108	9.9	12
16	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. <i>Neoplasia</i> , 2017 , 19, 972-981	6.4	12
15	Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo. <i>Neoplasia</i> , 2007 , 9, 322-31	6.4	6
14	Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma. <i>Cancers</i> , 2020 , 12,	6.6	3
13	Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. <i>Haematologica</i> , 2021 , 106, 3176-3187	6.6	3
12	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. <i>Cancers</i> , 2020 , 12,	6.6	3
11	LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib. <i>FASEB BioAdvances</i> , 2020 , 2, 339-353	2.8	2
10	The Role of the Cancer Stem Cell Niche in Cancer Initiation and Progression 2014 ,		2
9	Androgen decreases osteoprotegerin expression in prostate cancer cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2007 , 10, 160-6	6.2	2
8	Macrophages in multiple myeloma: key roles and therapeutic strategies. <i>Cancer and Metastasis Reviews</i> , 2021 , 40, 273-284	9.6	2

7	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. <i>PLoS ONE</i> , 2020 , 15, e0228408	3.7	1
6	Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. <i>Blood</i> , 2014 , 124, 647-647	2.2	1
5	Characterization of the role of Samsn1 loss in multiple myeloma development. <i>FASEB BioAdvances</i> , 2020 , 2, 554-572	2.8	1
4	Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. <i>Molecular Oncology</i> , 2021 ,	7.9	1
3	Seed and soil revisited in multiple myeloma. <i>Blood</i> , 2021 , 137, 2282-2283	2.2	0
2	Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. <i>Blood</i> , 2019 , 134, 3099-3099	2.2	
1	Dasatinib (Sprycel™) Inhibits Osteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. <i>Blood</i> , 2008 , 112, 3214-3214	2.2	